Literature DB >> 10051080

Spontaneous intracerebral hemorrhage in critically ill patients: incidence over six years and associated factors.

A Oppenheim-Eden1, L Glantz, L A Eidelman, C L Sprung.   

Abstract

OBJECTIVE: Intracerebral hemorrhage (ICH) is associated with a high mortality. The present study sought to determine the incidence of spontaneous ICH in an intensive care unit (ICU) and associated factors.
DESIGN: A 6 year retrospective study.
SETTING: A general ICU in a university hospital. PATIENTS: All ICU patients developing ICH were included in the study. All trauma and neurosurgical patients were excluded, as well as patients who were admitted to the ICU because of ICH. MEASUREMENTS AND
RESULTS: During the study period 3032 patients were hospitalized in the ICU, and 834 were excluded. The remaining 2198 patients comprised the study population. Computed tomography of the head was performed in a total of 227 patients, and the 9 patients found to have new onset ICH comprise the group of interest. None of these patients were hypertensive. Seven of the patients had either a primary hematologic malignancy or bone marrow transplantation. Eight had thrombocytopenia of <100x10(9)/l (median 10x10(9)/l, range 3-150x10(9)/l), and in 6 it preceded ICH by 5 days or more. Only in one patient were both PTT and PT prolonged. All were mechanically ventilated with high peak inspiratory pressure (PIP) (median 37 cm H2O, range 20-43 cm H2O). Arterial carbon dioxide tension (PaCO2) was considerably elevated (median 65 mm Hg, range 41-87 mm Hg). All of the patients had impaired renal and hepatic function (urea: median 14 mmol/l, range 9.9-52 mmol/l; bilirubin: median 94 micromol/l, range 20-360 micromol/l), and five had septicemia. Eight of the patients bled to other sites before they developed ICH. All patients died shortly after the diagnosis of ICH.
CONCLUSIONS: Spontaneous nonhypertensive ICH is a rare, fatal event in the ICU. Associated factors include thrombocytopenia, the need for mechanical ventilation, elevated PIP and PaCO2, sepsis, and impaired hepatic and renal function.

Entities:  

Mesh:

Year:  1999        PMID: 10051080     DOI: 10.1007/s001340050788

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  11 in total

1.  Effect of severe thrombocytopenia on patient outcome after liver transplantation.

Authors:  Chaker Ben Hamida; Jean-Yves Lauzet; Saida Rézaiguia-Delclaux; Christophe Duvoux; Daniel Cherqui; Philippe Duvaldestin; François Stéphan
Journal:  Intensive Care Med       Date:  2003-04-03       Impact factor: 17.440

2.  Spontaneous intracranial haemorrhage in critically ill patients with malignancies.

Authors:  Jeong-Am Ryu; Daesang Lee; Jeong Hoon Yang; Chi-Ryang Chung; Chi-Min Park; Gee Young Suh; Kyeongman Jeon
Journal:  Support Care Cancer       Date:  2016-02-11       Impact factor: 3.603

3.  Current role of activated protein C therapy for severe sepsis and septic shock.

Authors:  Philip S Barie
Journal:  Curr Infect Dis Rep       Date:  2008-09       Impact factor: 3.725

Review 4.  Systemic versus localized coagulation activation contributing to organ failure in critically ill patients.

Authors:  Marcel Levi; Tom van der Poll; Marcus Schultz
Journal:  Semin Immunopathol       Date:  2011-07-30       Impact factor: 9.623

5.  Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies.

Authors:  Jean-Louis Vincent; Simon Nadel; Demetrios J Kutsogiannis; R T Noel Gibney; S Betty Yan; Virginia L Wyss; Joan E Bailey; Carol L Mitchell; Samiha Sarwat; Stephen M Shinall; Jonathan M Janes
Journal:  Crit Care       Date:  2005-05-17       Impact factor: 9.097

Review 6.  Coagulation abnormalities in critically ill patients.

Authors:  Marcel Levi; Steven M Opal
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

7.  Thrombocytopenia in critically ill surgical patients: a case-control study evaluating attributable mortality and transfusion requirements.

Authors: 
Journal:  Crit Care       Date:  1999       Impact factor: 9.097

Review 8.  The safety profile of drotrecogin alfa (activated).

Authors:  Roberto Fumagalli; Mariano A Mignini
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

Review 9.  Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.

Authors:  Gordon R Bernard; William L Macias; David E Joyce; Mark D Williams; Joan Bailey; Jean-Louis Vincent
Journal:  Crit Care       Date:  2003-02-28       Impact factor: 9.097

Review 10.  Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis--practical aspects at the bedside and patient identification.

Authors:  Pierre-François Laterre; Xavier Wittebole
Journal:  Crit Care       Date:  2003-06-30       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.